About aTyr Pharma, Inc.
https://www.atyrpharma.comaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States.
CEO
Sanjay S. Shukla
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public N/A
Method of going public IPO
Full time employees 56
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-07-01 | Reverse | 1:14 |
ETFs Holding This Stock
Summary
Total 42
Showing Top 3 of 42
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 4
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Equal Weight 1
Sector Perform 1
Neutral 1
Showing Top 4 of 4
Price Target
Target High $17
Target Low $1
Target Median $1.25
Target Consensus $5.13
Market Cap $71.05 M
52w High $7.29
52w Low $0.64
P/E -0.85
Volume 1.35M
Outstanding Shares 97.99M
About aTyr Pharma, Inc.
https://www.atyrpharma.comaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $190K ▲ | $4.8M ▼ | $-25.74M ▼ | -13.55K% ▼ | $-0.26 ▼ | $-25.58M ▼ |
| Q2-2025 | $0 | $20.31M ▲ | $-19.53M ▼ | 0% | $-0.22 ▼ | $-19.93M ▼ |
| Q1-2025 | $0 | $15.77M ▲ | $-14.88M ▲ | 0% | $-0.17 ▲ | $-15.39M ▲ |
| Q4-2024 | $0 | $3.59M ▼ | $-14.97M ▲ | 0% | $-0.18 ▲ | $-15.64M ▲ |
| Q3-2024 | $0 | $18.14M | $-17.26M | 0% | $-0.23 | $-17.75M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $90.2M ▲ | $106.65M ▲ | $26.61M ▼ | $80.23M ▲ |
| Q2-2025 | $80.35M ▲ | $101.53M ▲ | $26.88M ▲ | $74.84M ▼ |
| Q1-2025 | $76.35M ▲ | $97.25M ▲ | $22.38M ▼ | $75.05M ▲ |
| Q4-2024 | $72.13M ▲ | $96.83M ▲ | $27M ▲ | $70.02M ▲ |
| Q3-2024 | $65.99M | $91.62M | $26.48M | $65.33M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-25.75M ▼ | $-20.48M ▼ | $-20.38M ▼ | $29.62M ▲ | $-11.24M ▼ | $-20.51M ▼ |
| Q2-2025 | $-19.53M ▼ | $-13.89M ▲ | $3.3M ▲ | $17.9M ▼ | $7.3M ▲ | $-13.9M ▲ |
| Q1-2025 | $-14.88M ▲ | $-15.42M ▼ | $-4.42M ▲ | $18.63M ▼ | $-1.21M ▼ | $-15.42M ▼ |
| Q4-2024 | $-14.97M ▲ | $-13.13M ▲ | $-6.08M ▼ | $18.84M ▲ | $-378K ▼ | $-13.16M ▲ |
| Q3-2024 | $-17.26M | $-13.16M | $17.95M | $-105K | $4.68M | $-13.17M |
CEO
Sanjay S. Shukla
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public N/A
Method of going public IPO
Full time employees 56
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-07-01 | Reverse | 1:14 |
ETFs Holding This Stock
Summary
Total 42
Showing Top 3 of 42
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 4
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Equal Weight 1
Sector Perform 1
Neutral 1
Showing Top 4 of 4
Price Target
Target High $17
Target Low $1
Target Median $1.25
Target Consensus $5.13